Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.

Singh B, Smith JA, Axelrod DM, Ameri P, Levitt H, Danoff A, Lesser M, de Angelis C, Illa-Bochaca I, Lubitz S, Huberman D, Darvishian F, Kleinberg DL.

Breast Cancer Res. 2014 Nov 11;16(6):463. doi: 10.1186/s13058-014-0463-1.

2.

Acromegaly: assessing the disorder and navigating therapeutic options for treatment.

Melmed S, Kleinberg DL, Bonert V, Fleseriu M.

Endocr Pract. 2014 Oct;20 Suppl 1:7-17; quiz 18-20. doi: 10.4158/EP14430.RA. Review. No abstract available.

PMID:
25374336
3.

Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials.

Newman CB, Carmichael JD, Kleinberg DL.

Pituitary. 2015 Jun;18(3):297-305. doi: 10.1007/s11102-014-0571-z. Review.

PMID:
24810900
4.

Growth hormone should be used only for approved indications.

Clemmons DR, Molitch M, Hoffman AR, Klibanski A, Strasburger CJ, Kleinberg DL, Ho K, Webb SM, Bronstein MD, Bouillon R, Ben-Shlomo A, Hamrahian AH, Chanson P, Barkan AL, Merriam GR, Blackman MR, Salvatori R.

J Clin Endocrinol Metab. 2014 Feb;99(2):409-11. doi: 10.1210/jc.2013-4187. Epub 2013 Dec 11. No abstract available.

5.

Breast cancer risk in BRCA1 mutation carriers: insight from mouse models.

Barcellos-Hoff MH, Kleinberg DL.

Ann Oncol. 2013 Nov;24 Suppl 8:viii8-viii12. doi: 10.1093/annonc/mdt305. Review.

PMID:
24131977
6.

Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.

Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ, Melmed S; International HypoCCS Advisory Board.

J Clin Endocrinol Metab. 2013 Mar;98(3):980-8. doi: 10.1210/jc.2012-2684. Epub 2013 Jan 23.

7.

Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression.

Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M, Strasburger CJ, Kleinberg DL, Melmed S, Mamluk R.

J Clin Endocrinol Metab. 2012 Jul;97(7):2362-9. doi: 10.1210/jc.2012-1179. Epub 2012 Apr 26.

PMID:
22539587
8.

Alternative approach to insulin-like growth factor-1 inhibition for treatment of breast cancer.

Ameri P, Danoff A, Kleinberg DL.

J Clin Oncol. 2012 Apr 20;30(12):1395-6; author reply 1396. doi: 10.1200/JCO.2011.40.6991. Epub 2012 Mar 5. No abstract available.

PMID:
22393094
9.

The pivotal role of insulin-like growth factor I in normal mammary development.

Kleinberg DL, Barcellos-Hoff MH.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):461-71, vii. doi: 10.1016/j.ecl.2011.06.001. Review.

PMID:
21889714
10.

Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis.

Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lamberts SW, Clemmons DR; HypoCCS International Advisory Board.

J Clin Endocrinol Metab. 2011 Jul;96(7):2255-61. doi: 10.1210/jc.2011-0448. Epub 2011 May 4.

PMID:
21543424
11.

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society.

J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692. Review.

PMID:
21296991
12.

Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.

Newman CB, Frisch KA, Rosenzweig B, Roubenoff R, Rey M, Kidder T, Kong Y, Pursnani A, Sedlis SP, Schwartzbard A, Kleinberg DL.

J Clin Endocrinol Metab. 2011 Jan;96(1):122-32. doi: 10.1210/jc.2010-1204. Epub 2010 Oct 6.

PMID:
20926529
13.

Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.

Kleinberg DL, Ameri P, Singh B.

Pituitary. 2011 Mar;14(1):44-52. doi: 10.1007/s11102-010-0257-0.

PMID:
20890664
14.

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.

Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S; SALSA Study Group.

Pituitary. 2010 Jun;13(2):115-22. doi: 10.1007/s11102-009-0207-x.

15.

Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects.

Woodmansee WW, Hartman ML, Lamberts SW, Zagar AJ, Clemmons DR; International HypoCCS Advisory Board.

Clin Endocrinol (Oxf). 2010 Jan;72(1):59-69. doi: 10.1111/j.1365-2265.2009.03612.x. Epub 2009 May 4.

PMID:
19438908
16.

Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Kleinberg DL, Wood TL, Furth PA, Lee AV.

Endocr Rev. 2009 Feb;30(1):51-74. doi: 10.1210/er.2008-0022. Epub 2008 Dec 15. Review. Erratum in: Endocr Rev. 2012 Dec;33(6):1038.

17.

IGF-I, GH, and sex steroid effects in normal mammary gland development.

Kleinberg DL, Ruan W.

J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):353-60. doi: 10.1007/s10911-008-9103-7. Epub 2008 Nov 25.

PMID:
19034633
18.

Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.

Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL.

Clin Endocrinol (Oxf). 2008 Jan;68(1):66-71. Epub 2007 Aug 29.

PMID:
17760883
19.
20.

GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90.

Carmichael JD, Danoff A, Milani D, Roubenoff R, Lesser ML, Livote E, Reitz RE, Ferris S, Kleinberg DL.

Clin Endocrinol (Oxf). 2006 Aug;65(2):169-77.

Supplemental Content

Loading ...
Support Center